Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic(TM) Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
Stock Information for Aditxt Inc.
Loading
Please wait while we load your information from QuoteMedia.